Does Bryan Johnson's result mean CJC-1295 is dangerous?

No. A single self-documented experiment is a data point, not a clinical trial, and cannot establish safety or harm for anyone else. His account is useful mainly as a reminder to measure biomarkers rather than assume benefit. Nothing here is medical advice.

Is this celebrity endorsing New-U Research Compounds?

No. This article reports on independent press coverage of a public figure. Bryan Johnson is not affiliated with, sponsored by, or endorsing New-U Research Compounds, and nothing here is medical advice.

Shop by goal

Metabolic Research

GH-Axis Research

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Popular compounds

Research resources

Bryan Johnson's CJC-1295 Experiment: What His 2026 Results Showed

Q: What peptide did Bryan Johnson experiment with?

In a 2026 public write-up, Bryan Johnson described a measured self-experiment with CJC-1295, a GHRH analog, and reported adverse markers - the basis for his argument that peptides are "not only good." This reports his public account, not medical advice.

Short answer: In a widely shared 2026 write-up, longevity self-experimenter Bryan Johnson argued that “peptides are not only good” - describing a measured trial of CJC-1295 , a growth-hormone-releasing-hormone (GHRH) analog, that he says produced unwanted markers rather than clean benefits. It is one of the most useful celebrity data points precisely because it is skeptical : a quantified n-of-1 that pushes against the “peptides fix everything” narrative. Editorial note: New-U reports independent press coverage here; Bryan Johnson is not affiliated with or endorsing New-U, and nothing here is medical advice.

Most celebrity peptide coverage is enthusiastic. Bryan Johnson’s is not - and that is what makes it worth reading carefully. Known for the extreme self-measurement of his longevity project, Johnson published a 2026 account (widely circulated via his Substack) titled around the idea that people mistakenly believe peptides are only good . He described running CJC-1295 and reported that his own biomarker tracking turned up adverse signals. This page summarises that public account and pairs it with what the CJC-1295 research literature actually describes - it is not medical advice, and Johnson is not affiliated with New-U.

What did Bryan Johnson say about CJC-1295?

Per his own 2026 write-up, Johnson approached CJC-1295 the way he approaches everything: as a measured experiment with before-and-after data rather than a vibe. His public framing was that the compound did not deliver the clean upside he had hoped for, and that some of the markers he tracks moved in the wrong direction - the basis for his broader argument that peptides carry real trade-offs and are “not only good.” We are reporting the existence and thrust of that account; readers should consult his primary post for the exact metrics he cites, and remember an n-of-1 is a data point, not a trial.

What is CJC-1295?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). In the research literature it is studied for its ability to stimulate the body’s own pulsatile release of growth hormone, and it is frequently paired with a growth-hormone secretagogue such as ipamorelin. It comes in two forms - with and without DAC (drug affinity complex), which changes the half-life. Our CJC-1295 + ipamorelin research guide covers the mechanism, and hexarelin vs CJC-1295 compares it with a different secretagogue class.

Why a skeptical data point matters

The value of Johnson’s account is not that it “proves” CJC-1295 is harmful - one person’s biomarkers cannot do that. Its value is that it models the right posture: measure, don’t assume. Growth-hormone-axis compounds can shift IGF-1, glucose handling and other markers, which is exactly why they belong in a monitored research context rather than a casual one. When a high-profile figure whose entire brand is optimisation reports a compound didn’t optimise him, that is a healthy counterweight to the influencer enthusiasm that dominates the rest of this beat.

The honest caveat. Johnson’s report is a single, self-documented experiment - it is neither a clinical trial nor evidence that the compound is safe or unsafe for anyone else. A public figure naming a compound is a cultural signal, not clinical proof. For the framework we use to separate a public statement from an approved medicine from a preliminary research compound, see celebrity peptide claims vs scientific research.

Frequently Asked Questions

What peptide did Bryan Johnson experiment with? In a 2026 public write-up he described a measured self-experiment with CJC-1295 (a GHRH analog) and reported adverse markers - arguing peptides are “not only good.” Reported as his public account, not medical advice.

What is CJC-1295? A synthetic GHRH analog studied for stimulating the body’s own growth-hormone release, often paired with ipamorelin; sold in DAC and no-DAC forms.

Does his result mean CJC-1295 is dangerous? No - an n-of-1 is a data point, not a trial, and cannot establish safety or harm for others. Its value is the “measure, don’t assume” posture. Nothing here is medical advice.

Is Bryan Johnson endorsing New-U? No. This reports his independent public write-up. He is not affiliated with or endorsing New-U; nothing here is medical advice.

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research